Bo Wang, Runxia Tian, Zhao-Jun Liu, Alan Livingstone, Omaida C. Velazquez
Surgery, University of Miami, Miami, FL.
OBJECTIVES: Repeated, low-dose injections of streptozotocin (STZ) create a model of type II diabetes mellitus. We utilize this model to investigate the potential pro-repair effect of syngeneic (equivalent to autologous) bone marrow-derived mesenchymal stem cells (BMD-MSC) in diabetes.
METHODS: STZ (40mg/kg) was administered, daily, for five days, i.p., in C57BL6 mice (n=12). Weekly blood glucose levels (BG) were monitored by 2-hour glucose tolerance test (GTT) for 5 weeks after. Glucose intolerance (150<BG<200mg/dL) was used as the trigger for treatment. The mice were then divided in two groups (n=6/group). Control group received PBS and treatment group received MSC (1x10^6), by tail vein infusion. MSC were obtained by culturing BMD cells from donor mice (n=3) in MesenCult® medium. β-cell activity was measured by immunohistochemistry, and serum level of insulin was assessed by C-peptide test.
RESULTS: At baseline and post-STZ-induction, GTT between control and treatment group did not differ significantly. However, at week 3 the MSC treatment group's GTT normalized and the effect is sustained by week 5 (Figure 1). Control group continues to have significant glucose intolerance. Longer follow-up is ongoing.
CONCLUSIONS: Systemic injection of a single MSC treatment improves the glucose tolerance in a murine model of type II diabetes. The findings will require confirmation in genetic murine models, yet depict a highly promising novel concept for the treatment of diabetes.
AUTHOR DISCLOSURES: Z. Liu
: Nothing to disclose; A. Livingstone
: Nothing to disclose; R. Tian
: Nothing to disclose; O. C. Velazquez
: Nothing to disclose; B. Wang
: Nothing to disclose.
Posted April 2013